Galectin-3 has been extensively studied as an immunohistochemical marker of thyroid malignancy, and a high diagnostic accuracy has been reported even for difficult pathological diagnoses, such as minimal invasive follicular carcinoma. We consequently hypothesized that the quantitative analysis of galectin-3 mRNA rather than the more observerdependent immunohistological determination might enhance the diagnostic workup of ambiguous thyroid lesions. In the present study, we set out to validate this approach by analyzing concomitantly the expression and production of galectin-3 in benign and malignant thyroid tumors by means of quantitative PCR and immunohistochemistry. Twenty-eight benign and 31 malignant thyroid samples were quantified by real-time PCR for the mRNA levels of galectin-3 and thyroglobulin. Galectin-3 protein expression was examined by immunohistochemistry in 13 benign and 14 malignant thyroid samples. There was a significant increase in galectin-3 at both the mRNA (12/20) and protein levels in papillary cancer (8/8), although the mRNA values overlapped partly with benign lesions. Surprisingly, only a focal and discrete galectin-3 immunoreactivity was seen in follicular cancer (1/5); no augmentation of the mRNA was found. The expression of the thyroid-specific gene thyroglobulin was highly variable in benign and malignant thyroid tissue. These results suggest that the quantitative measurement of galactin-3 mRNA is unlikely to be clinically useful and underscore the need for searching for novel markers for thyroid malignancies.
Fine-needle aspiration is the method of choice in evaluating clinically significant thyoid nodules. Although approximately 85% of the aspirated nodules are diagnosed as benign lesions, the remaining 15% are classified as microfollicular lesions, which means that no definite statement can be made as to their benign or malignant nature (1) . Subsequently, 90 -95% of these patients currently undergo unnecessary thyroidectomy. Moreover, the diagnosis of follicular thyroid cancer, which relies on the criteria of vascular invasion and capsular infiltration, remains a challenge, particularly in the minimally invasive variant of follicular cancer, for which debates arise about what constitutes a true capsular infiltration (2) . These problems have motivated the search for a suitable marker of malignancy that may improve the accuracy of the diagnosis and possibly reduce the number of unnecessary surgical interventions (3) .
Two members of the lectin family, galectin-1 and galectin-3, have received particular attention. Lectins are carbohydrate-binding proteins that recognize specific oligosaccharide structures and ligands. Galectin-1 and galectin-3 belong to the family of galactoside-binding proteins, and they are polypeptides consisting of a short amino-terminal sequence, a repetitive collagen-like sequence that is rich in proline, glycine, and tyrosine and a COOHterminal carbohydrate recognition domain (4) . Galectins are localized on the cell surface and within the extracellular matrix, as well as in the cytoplasm and the nucleus of cells, and may serve as receptors for proteins of the extracellular matrix, such as laminin and fibronectin (5) . Galectins are expressed in tissues such as colon, breast, and thyroid as well as in macrophages and activated endothelial cells, and they have been implicated in biological processes as diverse as cell growth, differentiation, apoptosis, inflammation, and angiogenesis (6 -11) .
Galectin-1 has been proposed to mediate cell-tocell and cell-to-matrix adhesion, to induce or to inhibit apoptosis; galectin-3 is known to mediate and inhibit cell adhesion and to participate in neutrophil and macrophage activation (5) .
Several studies have analyzed galectin-1 and galectin-3 expression in benign and malignant thyroid tissue. Although galectin-1 mRNA levels have been described to be increased in 28/40 (70%) papillary carcinomas, no change was seen in follicular carcinoma; moreover, galectin-1 protein levels were positive in all papillary carcinomas (12) . In a second study, an increase in galectin-1 and galectin-3 protein expression was observed in 16/16 (100%) papillary and 7/7 (100%) follicular carcinomas; the normal or benign samples remained negative (13) . A further study showed a positive galectin-3 immunoreactivity in 18/18 (100%) papillary and 14/17 (82%) follicular carcinomas, whereas only 3/29 (10%) follicular adenomas stained positively (14) . Along the same lines, the most comprehensive study thus far showed immunohistochemical positivity for galectin-3 in 195/201 (97%) papillary and 54/57 (95%) follicular carcinomas; the analysis of galectin-3 in benign thyroid tissue was largely negative in 75/75 (100%) normal control cases, 50/50 (100%) hyperplastic lesions, and 121/ 125 (97%) follicular adenomas (15) . Subsequently, galectin-3 positivity could even be detected in 17/17 (100%) minimal invasive follicular cancer carcinomas, supporting the view of galectin-3 as an early tumor marker of thyroid cancer (16) .
However, in another study, galectin-3 positivity was found only in 4/9 (44%) follicular carcinomas, whereas 27/28 (96%) papillary carcinomas were positive (17) . Recently, a quantitative study of galectin-3 mRNA showed no significant differences between follicular carcinomas and benign thyroid tissue (18) . Intriguingly, another study indeed found galectin-3 immunoreactivity in 18/20 (90%) follicular carcinomas but also found galectin-3 positivity in 14/17 (82%) follicular adenomas (19) .
In summary, although there is strong evidence for a potential role of galectin-3 as a marker for thyroid cancers, several studies have recently challenged the notion of galectin-3 as a tumor marker for follicular carcinoma (17) (18) (19) . As immunohistochemical analysis is highly observer dependent, we hypothesized that the quantitative determination of galectin-3 mRNA levels by means of real-time quantitative PCR might be a more reliable and reproducible method that also could be applicable to fine-needle aspiration. Hence, we analyzed in the present study the expression levels of galectin-3 mRNA in normal and malignant thyroid tissue, comparing it with protein expression levels.
MATERIALS AND METHODS

Patients and Samples
Specimens of 20 papillary (including 1 follicular variant and 1 tall cell variant), 7 follicular (4 minimal invasive and 3 widely invasive, including 1 oxyphilic variant each), and 4 poorly differentiated thyroid cancers (1 anaplastic carcinoma, 3 insular carcinomas), 9 adenomas, 9 hyperplasias, and 10 normal thyroid glands were collected from 59 patients who were undergoing surgery at the University Hospital Hamburg (A.F.), Hamburg, Germany and University Hospital Essen (A.F., K.S.), Essen, Germany and University Hospital Geneva (J.R., A.S., M.T.), Geneva, Switzerland from January 1999 to December 2001. Information concerning age, sex, pTNM, and histologic subtype was retrieved by reviewing the pathology reports. After surgery, the material was snap-frozen in liquid nitrogen and stored at Ϫ80°C for subsequent RNA extraction. The tissue block used for RNA extraction was verified histologically, and samples that did not contain Ն60% tumor cells were excluded from the study. Original paraffin blocks were accessible for 13 benign and 14 tumor samples (see Table 1 ) studied at two centers (Geneva and Essen).
Immunohistochemistry
Routinely processed formalin-fixed, paraffinembedded tissue sections were mounted onto coated slides and dried at 40°C overnight; then they were deparaffinized with xylene and rehydrated with graded ethanol concentrations. Endogenous peroxidase activity was blocked by incubation with 1.1% H 2 O 2 for 10 minutes. Nonspecific binding of the second antibody was avoided by preincubation with normal rabbit serum for 15 minutes. The sections were then incubated with the primary antibody to human galectin-3 (Clone: B2C10, diluted 1: 50; BD Biosciences-BD Pharmingen, San Diego, CA); at 4°C overnight. The secondary antibody was detected with a standard ABC technique using 3,3'-diaminobenzidine-tetrahydrochloride dihydrate (3,3'-diaminobenzidine) as chromogen.
Sections of normal colonic mucosa were used as external positive controls; omission of the primary antibody, as negative control. Sections were scanned at low power to identify areas that were evenly labeled, and an estimate of galectin-3-positive cells was scored semiquantitatively, as follows: 0 ϭ all cells negative; 1 ϭ Ͻ30% positive cells; 2 ϭ 30 -60% positive cells; 3 ϭ Ͼ60% positive cells.
RNA Extraction and cDNA Synthesis
After the presence of tumor tissue was ascertained by histological examination of frozen sections from the tissue specimens, total RNA was extracted by using the TRIzol Reagent according to the manufacturer's instructions (LifeTechnologies Inc.) and quantified spectrophotometrically; its integrity was verified by gel electrophoresis. We reverse-transcribed 2.5 g of total RNA in a total volume of 32 L using 400 IU of Moloney murine leukemia virus reverse transcriptase (LifeTechnologies Inc.), 0.3 U/L of RNasin (Promega Corp., Madison, WI), 7.5 M oligo(dN) 6 , 1.2 mM dNTP, and 5ϫ First strand buffer with 12 mM dithiothreitol and RNase-free H 2 O.
Primers and Plasmids
Primers for galectin-3 and thyroglobulin were chosen with the assistance of the computer program Primer3 (20) . The nucleotide sequences for the different primer pairs were as follows:
Galectin-3: sense 5' ATGCAAACAGAATTGCTT-TAGATT 3', antisense 5' AGTTTGCTGATTTCATT-GAGTTTT 3' (280 bp); thyroglobulin: sense 5' ATG-CACTGGGGAACTCAAAG 3', antisense 5' TGAGGCTGAGAACACAATGG 3' (200 bp). The PCR products of galectin-3 and thyroglobulin (Fig. 1A) were cloned into the vector pCR3.1 (Invitrogen, Paisley, UK) and served as external standards.
Quantitative Real-Time RT-PCR
Copy numbers of galectin-3 mRNA and thyroglobulin mRNA were determined by quantitative real-time RT-PCR using a Lightcycler (Roche Diagnostics, Switzerland) with standard curves based on the serial dilution of the appropriate plasmid (21) (22) (23) . DNA Master SYBR Green I (Roche Molecular Biochemicals, Switzerland) was used for the two genes analyzed. Amplifications (10 L reaction volume) were performed in glass capillary tubes; 2 L of cDNA, 1.2 L of magnesium chloride (2.8 mM), 4.8 L of sterile water, 1 L of SYBR Green I, and 1 L of each primer (0.5 M) were used. The RT-PCR reactions were performed according to the Lightcycler standard protocol using the following annealing temperatures: galectin-3, 56°C and thyroglobulin, 57°C. The specificity of the amplicon was confirmed by restriction digestion and sequencing.
Cycle threshold values and calculated values were determined using the Lightcycler software (Version 5.32). Absolute mRNA concentrations were calculated from serially diluted (1:10) standard curves over a range of four to five orders and expressed as moles per microgram of RNA. Two separate runs were performed for each sample and the mean was calculated. To estimate the interrun variation, the values of the two independent runs of each gene of all samples were compared, and the correlation was nearly perfect (Fig. 1B-C) . RNA samples without addition of reverse transcriptase served as negative controls.
Statistical Analyses
Differences between the different pathological categories were evaluated using the Mann-Whitney U test, and correlations among parameters were assessed using the Spearman rank statistics with SYSTAT 10.01 (SPSS Inc, Chicago, IL). A P value of Ͻ.05 was considered as significant. The median values are marked by a dashed line on the graphs. 
RESULTS
Galectin-3 Expression in Benign Versus Papillary and Follicular Cancer
Galectin-3 expression varied between 0.03 and 2.75 amol/g RNA in normal and benign thyroid tissue (normal: n ϭ 10, range 0.05-2.75; hyperplasia: n ϭ 9, range 0.23-2.14; adenoma: n ϭ 9, range 0.03-2.14), with no significant changes among these groups.
A similar pattern was observed in follicular cancer (n ϭ 7; range 0.3-2.1 amol/g RNA); thus, no difference was found between the benign tissue and the follicular cancer group (Fig. 2A) . Neither extension of the tumor (minimal or widely invasive), nor oxyphilic differentiation had significant implications on Gal-3 expression (Table 1 ). In papillary cancer (n ϭ 20), the values varied between 0.4 and 20.15 amol/g of RNA. A subgroup of these patients' cases (n ϭ 4), including the case of follicular variant, had values of Ͼ10 amol/g RNA. Though the overall increase observed in the papillary cancer group was 3.5-fold (P ϭ .0001), 50% of the patients with papillary cancer had galectin-3 levels that overlapped with the levels found in benign lesions. Poorly differentiated cancers (n ϭ 4, including one anaplastic thyroid cancer) expressed galectin-3 at levels similar to those in papillary tumors.
Thyroglobulin Expression in Benign Versus
Papillary and Follicular Cancer
Thyroglobulin expression showed a high variability ranging from 0.1-367 fmol/g RNA in normal and benign thyroid tissue (normal: 0.6 -367; hyperplasia: 0.1-2.7; adenoma: 0.3-228 fmol/g RNA). No significant changes were observed compared with the papillary and follicular cancer group (Fig. 2B) . Thyroglobulin expression was highly variable, also 
Characterization of Galectin-3 Protein Expression by Immunohistochemistry in Benign and Malignant Lesions of the Thyroid
Seven of 8 (88%) hyperplastic nodules were negative for galectin-3; in one sample, histologically benign pseudopapillary structures stained positive. Among five follicular adenomas, one sample was slightly positive for galectin-3 (20%).
All eight papillary thyroid carcinomas stained positive for galectin-3, (100%) whereas four (80%) of five of the follicular carcinomas were completely negative for galectin-3, and one case was focally positive (Ͻ5% and considered as negative; Table 1 ; Fig. 3 ). The single case of an anaplastic carcinoma examined was negative for galectin-3 immunostaining. To assess the correlation between mRNA and protein, the correlation coefficient was calculated and yielded a value of r 2 ϭ 0.65 (P ϭ .0001). Although all papillary carcinomas were positive for galectin-3 immunostaining, two corresponding mRNA values were not increased (cases 2 and 4).
DISCUSSION
Fine-needle aspiration and subsequent cytopathologic analysis are pivotal steps in the workup of a thyroid nodule, and certain pathologic situations exist in which the cytopathological report is equivocal ("microfollicular lesion"), and surgery is usually the only means by which to establish a definite diagnosis. Hence, reliable markers for thyroid cancers would be welcome to avoid unnecessary surgical interventions.
Members of the galactose-binding proteins have been extensively studied as potential markers of thyroid malignancy (1, 5, 12, 24 -27) . Recently, a large multicenter study compared galectin-3 in benign and malignant thyroid tissue and reported an excellent sensitivity (99%) and specificity (98%) for this marker (15) . As immunohistochemical analysis is necessarily semiquantitative and strongly dependent on the protocol used and the experience of the observer, we wanted to assess whether galectin-3 mRNA levels would also correlate with the immunohistochemical diagnosis and whether a quantita- tive cutoff may be useful in differentiating benign from malignant thyroid tumors.
Real-time quantitative PCR has been established as a reliable and accurate quantitative method for the analysis of mRNA levels (23) . So far, mainly thyroid-specific genes such as thyroglobulin or sodium-iodine symporter have been studied (9, 28) . With the aim of performing quantitative PCR on fine-needle aspirations, a recently published work studied galectin-3 mRNA quantitatively in tissue specimens of different thyroid malignancies but did not observe an increase in galectin-3 in follicular cancer (18) .
Regarding the literature, there are just a few studies investigating galectin-3 with material obtained by fine-needle aspiration. The methodological approach is quite variable; some apply immunocytochemistry (14, 15, 16, 29) , some apply RT-PCR (30), and some apply both (26, 31) . It has been shown that RT-PCR alone is not a reliable method for the evaluation of the galectin-3 expression, because macrophages and activated endothelial cells express galectin-3 (15) . Furthermore, positive results in benign lesions such as colloid goiters or Hashimoto's thyroiditis are potential pitfalls when no cytological control is performed. However, most of the publications report detection of galectin-3 in nearly all cases of papillary and follicular carcinomas, regardless of which method was used. Just a few positive cases of follicular adenomas are described.
These findings cannot be supported by our study, in which we were working with a series of 59 thyroid tissue samples. In concordance with other studies, a significant increase in galectin-3 (at the protein level and, to a lesser extent, at the mRNA level) was observed in papillary cancers when compared with adenomas. However, in two cases of papillary cancer the galectin-3 mRNA was not increased, whereas immunohistochemistry was clearly positive. This observation indicates that the analysis at the protein level is more feasible than quantitative PCR, and we think that this may be due to degradation of mRNA.
In fact, all immunohistochemically analyzed papillary carcinomas stained positively for galectin-3; unfortunately, in a further eight papillary carcinomas with normal galectin-3 mRNA levels, no blocks were available for immunohistological analysis. We had just one case of the follicular variant in our study group; thus, our results concerning this interesting entity are not representative enough to be compared with those of other studies (15, 30) .
In our series, both mRNA and protein levels of galectin-3 were not increased in follicular cancer. These results are in agreement with those of two previously published studies that did not find an increase in galectin-3 mRNA, much less galectin-3 positivity in immunohistochemical analysis (17, 18) . However, the majority of the studies published so far describe an increased galectin-3 protein expression in thyroid carcinomas and, in particular, in follicular carcinomas. Whether the observed differences are related to tumor heterogeneity, pathological classification, or methodological problems remains unclear. In our study, no statistical significant differences could be observed in the four cases of minimally invasive and three cases of widely invasive follicular carcinomas. In contrast to other publications, our two cases of follicular carcinomas with oxyphilic differentiation showed no or minimal expression of galectin-3 by immunohistochemistry and quantitative PCR (15, 30) .
The fact that in the case of anaplastic carcinoma, quantitative PCR revealed the presence of a considerable amount of galectin-3 mRNA, whereas immunohistochemistry was completely negative, may be explained by the fact that investigations were performed on different tissue blocks or by overfixation of the material. However, cases of negative immunohistochemistry results in anaplastic carcinoma have already been described (32) .
As reported by other investigators, we observed a large variability in expression of thyroglobulin in all disease categories (9, 28). Although we observed an increased median value of thyroglobulin in thyroid cancers, this was not statistically significant.
In summary, we established and validated the quantitative analysis of galectin-3 mRNA levels by means of quantitative real-time PCR in benign and malignant thyroid tissue. We observed a significant increase in galectin-3 on mRNA and protein levels in papillary thyroid cancers. No follicular thyroid cancer was positive with regard to galectin-3 mRNA levels. Hence, galectin-3 expression or immunoreactivity do not appear to be useful tools in distinguishing adenomas from follicular cancers in cytological or histological specimens. However, it remains to be seen whether galectin-3 will prove useful in detecting the follicular variant of papillary cancers or a multifocal spread on histological material.
